Low-pro­file Thar Phar­ma takes a $50M fli­er on a weak IPO mar­ket

The biotech IPO mar­ket has been show­ing signs of life late­ly. But that of­fers no guar­an­tees for Thar Phar­ma­ceu­ti­cals, a vir­tu­al biotech far off the in­dus­try’s beat­en path push­ing a re­for­mu­lat­ed pain med that so far has on­ly been tried in a tiny safe­ty study.

Thar’s S-1 notes that the Pitts­burgh-based com­pa­ny has raised about $16.5 mil­lion so far, enough to pay for a Phase I study of T121, an oral for­mu­la­tion of the IV pain med zole­dron­ic acid. It’s their on­ly pipeline drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER